The large GAAP EPS miss is partly non-cash, but the CFO departure and board turnover add execution risk. Monitor the contingent $5.6M financing milestone (ReWalk sales +150% or stock at $13.80) for potential dilution. Revenue growth and cash improvement are positive, but margin compression and reliance on non-GAAP adjustments warrant caution.
Price Chart
Executive Summary
Lifeward reported Q2 2026 revenue of $6.6M (+16% YoY), slightly above consensus, but GAAP EPS of -$4.12 missed the -$1.28 estimate by 222% due to $6.9M in non-cash warrant remeasurement charges. Cash improved to $9.4M post a $5.6M financing, and the company highlighted a new distribution partnership with Ottobock Care, though gross margin contracted to 41% and the CFO announced departure.
Key Financial Metrics
Key Facts
- Revenue $6.6M (+16% YoY) vs consensus $6.5M (in-line)
- GAAP EPS -$4.12 vs consensus -$1.28 (strong miss)
- Non-GAAP EPS -$1.46 vs consensus -$1.28 (miss)
- Gross margin 41% vs 44% a year ago, pressured by tariffs, FX, and Oramed revenue share
- Cash and equivalents $9.4M at June 30, 2026, up from $2.2M at Dec 31, 2025
- CFO Almog Adar departing effective September 30, 2026
- Board chairman and two directors stepped down August 13, 2026
- Launched pilot program with Ottobock Care for ReWalk exoskeleton distribution
Financial Impact
GAAP net loss of $11.5M in Q2 2026, driven by $6.9M non-cash fair value charges on warrants; revenue grew $0.9M YoY but gross profit margin declined 3ppts
Risk Factors
- Dilution from convertible notes and warrant liabilities
- CFO transition and board changes may disrupt strategy
- Gross margin headwinds from tariffs and FX
- Contingent financing may not be achieved, limiting growth capital
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345381 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $7.45 $7.11 | ▼ −4.56% | ▼ −2.57% | $5.85 (−21.48%) |
Aug 14, 2026 7w ago | Press Release | $7.45 $7.11 | ▲ +4.56% | ▲ +2.57% | $5.85 (+21.48%) |
Aug 11, 2026 7w ago | EFFECT | $7.57 $7.40 | ▲ +2.18% | ▲ +1.12% | $5.85 (+22.67%) |
Aug 7, 2026 8w ago | Press Release | $7.69 $6.98 | ▼ −9.17% | ▼ −8.78% | $5.85 (−23.88%) |
May 19, 2026 19w ago | 8-K | $6.40 $6.98 | ▲ +9.06% | ▲ +8.08% | $5.85 (−8.59%) |
May 15, 2026 20w ago | 8-K | $6.70 $6.96 | ▼ −3.81% | ▼ −1.69% | $5.85 (+12.69%) |
May 15, 2026 20w ago | Press Release | $6.70 $6.96 | ▼ −3.81% | ▼ −1.69% | $5.85 (+12.69%) |
May 13, 2026 20w ago | EFFECT | $6.63 $6.80 | ▼ −2.56% | ▼ −3.18% | $5.85 (+11.76%) |
May 11, 2026 20w ago | Press Release | $6.40 $6.98 | ▲ +9.09% | ▲ +9.40% | $5.85 (−8.59%) |
Apr 27, 2026 22w ago | S-3 | $7.09 $6.98 | ▲ +1.55% | ▲ +7.02% | $5.85 (+17.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access